Celularity/CELU

$4.00

9.29%
-
1D1W1MYTD1YMAX

About Celularity

Celularity Inc. is a clinical-stage biotechnology company. The Company is engaged in developing off-the-shelf placental-derived allogeneic cell therapies for the treatment of cancer and immune and infectious diseases. It operates through three business segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapy product candidates include T cells engineered with a chimeric antigen receptor (CAR), natural killer, cells, mesenchymal-like adherent stromal cells (MLASCs), and exosomes. These therapeutic candidates target indications across cancer, infectious and degenerative diseases. Its cell therapeutic programs include CYCART-19, CYCART-201, CYNK-001, CYNK-301, CYNK-302, APPL-001, and pEXO-001. CYCART-19 is a placental-derived CAR-T cell therapy, in development for the treatment of B-cell malignancies, initially targeting the cluster of differentiation 19. pExo-001 is developed for the treatment of osteoarthritis. APPL-001 is developed for the treatment of Crohn’s disease.

Ticker

CELU

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Robert Hariri

Employees

225

Headquarters

Florham park, United States

Celularity Metrics

BasicAdvanced
$79.73M
Market cap
-
P/E ratio
-$10.51
EPS
0.24
Beta
-
Dividend rate

Celularity Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,535.13% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$3.7M
27.59%
Net income
$-93.8M
95.82%
Profit margin
-2,535.13%
53.48%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Celularity stock

Buy or sell Celularity stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing